Lv2
117 积分 2023-05-24 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4小时前
待确认
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3天前
已完结
Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales
3天前
已完结
The lncRNA MEG3/miR‐16‐5p/VGLL4 regulatory axis is involved in etoposide‐induced senescence of tumor cells
22天前
已完结
Top advances of the year: Bladder cancer
27天前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
27天前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
27天前
已完结
Tertiary lymphoid structures in cancer
1个月前
已完结
Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer
1个月前
已完结
High intensity focused ultrasound ablation and antitumor immune response
1个月前
已完结
皖公网安备34019202002308
